Insights

Innovative Therapeutics TransCode Therapeutics is focused on developing targeted RNA-based cancer therapies using its proprietary TTX delivery platform, which offers a promising avenue for partnerships in innovative oncology treatments.

Recent Expansion The company's recent acquisition of Polynoma LLC and strategic appointments, including new CEO Philippe Calais, indicate active growth and an openness to forming alliances to expand its pipeline and market presence.

Clinical Progress With successful Phase 1a trial results establishing safety and dosing, TransCode is advancing toward late-stage development, providing opportunities for investors and partners interested in early-stage clinical assets.

Financial Stability Receiving a substantial $25 million investment from CK Life Sciences and generating revenue between $1M and $10M, TransCode demonstrates solid financial backing and potential for scaling therapeutic development and commercialization.

Market Positioning Positioned as an emerging leader in immuno-oncology with a focus on metastatic cancer, TransCode offers strategic opportunities for collaborations across biotech sectors targeting unmet needs in aggressive and hard-to-treat cancers.

Similar companies to TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Tech Stack

TransCode Therapeutics, Inc. uses 8 technology products and services including Google Fonts API, Mustache, jQuery, and more. Explore TransCode Therapeutics, Inc.'s tech stack below.

  • Google Fonts API
    Font Scripts
  • Mustache
    Javascript Frameworks
  • jQuery
    Javascript Libraries
  • ScrollReveal
    Javascript Libraries
  • reCAPTCHA
    Security
  • Cloudflare Bot Management
    Security
  • Adobe Fonts
    Web Fonts
  • Apache
    Web Servers

Media & News

TransCode Therapeutics, Inc.'s Email Address Formats

TransCode Therapeutics, Inc. uses at least 1 format(s):
TransCode Therapeutics, Inc. Email FormatsExamplePercentage
First.Last@transcodetherapeutics.comJohn.Doe@transcodetherapeutics.com
48%
Last@transcodetherapeutics.comDoe@transcodetherapeutics.com
3%
Last.F@transcodetherapeutics.comDoe.J@transcodetherapeutics.com
1%
First.Last@transcodetherapeutics.comJohn.Doe@transcodetherapeutics.com
48%

Frequently Asked Questions

Where is TransCode Therapeutics, Inc.'s headquarters located?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s main headquarters is located at 73b Chapel Street Newton, Massachusetts 02458 United States. The company has employees across 2 continents, including North AmericaEurope.

What is TransCode Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s official website is transcodetherapeutics.com and has social profiles on LinkedInCrunchbase.

What is TransCode Therapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does TransCode Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of February 2026, TransCode Therapeutics, Inc. has approximately 17 employees across 2 continents, including North AmericaEurope. Key team members include Chief Executive Officer: Q. L.Ceo & Chairman, Transcode Therapeutics (nasdaq: Rnaz): P. C.Chief Technology Officer: Z. M.. Explore TransCode Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does TransCode Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does TransCode Therapeutics, Inc. use?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s tech stack includes Google Fonts APIMustachejQueryScrollRevealreCAPTCHACloudflare Bot ManagementAdobe FontsApache.

What is TransCode Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc.'s email format typically follows the pattern of First.Last@transcodetherapeutics.com. Find more TransCode Therapeutics, Inc. email formats with LeadIQ.

How much funding has TransCode Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of February 2026, TransCode Therapeutics, Inc. has raised $10M in funding. The last funding round occurred on Mar 23, 2025 for $10M.

When was TransCode Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
TransCode Therapeutics, Inc. was founded in 2016.

TransCode Therapeutics, Inc.

Biotechnology ResearchMassachusetts, United States11-50 Employees

TransCode's goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. 

TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

Important Notice: Recruitment Fraud Alert
We are aware of recruitment scams in which fraudsters pose as representatives of TransCode Therapeutics to deceive job seekers. Please note the following to protect yourself:
    •    We NEVER ask for payment or personal financial information during the recruitment process.
    •    All legitimate communication from our team will come from an official @transcodetherapeutics.com email address 
    •    Our hiring process always includes formal interviews—either virtual or in-person.
    •    If you receive a  job offer claiming to be from us, please do NOT respond. Report it to info@transcodetherapeutics.com.

Section iconCompany Overview

Headquarters
73b Chapel Street Newton, Massachusetts 02458 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $10M

    TransCode Therapeutics, Inc. has raised a total of $10M of funding over 15 rounds. Their latest funding round was raised on Mar 23, 2025 in the amount of $10M.

  • $1M$10M

    TransCode Therapeutics, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $10M

    TransCode Therapeutics, Inc. has raised a total of $10M of funding over 15 rounds. Their latest funding round was raised on Mar 23, 2025 in the amount of $10M.

  • $1M$10M

    TransCode Therapeutics, Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.